Streetbeat News

Price Targets

ARVN

Analyst ratings for Arvinas (NASDAQ:ARVN) show varied sentiments, with recent updates indicating an average 12-month price target of $45.83, a significant increase from the previous $36.67. Analysts from firms like Goldman Sachs and Wells Fargo have adjusted their ratings and price targets, reflecting evolving market conditions and Arvinas's performance. Despite the optimistic analyst projections, Arvinas faces challenges such as below-average market capitalization, revenue growth below sector average, and poor profitability indicators like net margin and ROE.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 1:00 pm

SWI

JP Morgan analyst Pinjalim Bora initiates coverage on SolarWinds (NYSE:SWI) with a Neutral rating and a price target of $14.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 1:00 pm

LII

JP Morgan analyst Stephen Tusa downgraded Lennox Intl (LII) from Neutral to Underweight and reduced the price target from $370 to $330.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 12:51 pm

STNE

UBS analyst Kaio Prato downgraded StoneCo (NASDAQ:STNE) from Buy to Neutral and set a new price target of $21.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 12:49 pm

BSX

CI

CNMD

DHR

EXTR

NYCB

PAGS

PSX

ROK

T

Wall Street analysts have updated their price targets and ratings for several US-listed companies, including notable changes for Boston Scientific Corporation (BSX), Danaher Corporation (DHR), Phillips 66 (PSX), Rockwell Automation (ROK), AT&T Inc. (T), Extreme Networks (EXTR), PagSeguro Digital Ltd. (PAGS), New York Community Bancorp (NYCB), CONMED Corporation (CNMD), and The Cigna Group (CI). These adjustments reflect analysts' latest views on these companies' future prospects.

Portfolio Pulse from Avi Kapoor

February 01, 2024 | 12:48 pm

CI

Deutsche Bank analyst George Hill upgraded Cigna Group (NYSE:CI) from Hold to Buy and increased the price target from $355 to $370.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 12:46 pm

EGHT

Needham analyst Ryan Koontz has reiterated a Buy rating on 8x8 (NASDAQ:EGHT) and maintained a $5 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 12:37 pm

IMRX

Needham analyst Ami Fadia reiterates a Buy rating on Immuneering (NASDAQ:IMRX) and maintains a $20 price target.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 12:34 pm

CFLT

Needham analyst Mike Cikos has reiterated a Buy rating on Confluent (NASDAQ:CFLT) and maintained a $30 price target on the stock.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 12:27 pm

BHE

Needham analyst James Ricchiuti maintains a Buy rating on Benchmark Electronics (NYSE:BHE) and raises the price target from $30 to $31.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 12:25 pm